Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug
Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug
Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug
Submitted by
admin
on August 21, 2018 - 10:12am
Source:
CP Wire
News Tags:
Allegro
Luminate
diabetic macular edema
clinical trials
diabetes
Headline:
Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug
snippet:
New CEO Has 25 Years Experience in the ophthalmic pharmaceutical space
Luminate met primary endpoints in Ph IIb study
Luminate is a first-in-class integrin peptide therapy for treating neovascular retinal diseases
Do Not Allow Advertisers to Use My Personal information
